HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antibody subclass profile and avidity during acute and chronic human Schistosoma mansoni infection.

Abstract
The avidity of IgA, IgM, IgG and IgG subclass antibodies against Schistosoma mansoni soluble egg antigen (SEA) was determined by ELISA in serum samples collected in 1995 from individuals in Brazil with acute (n = 36) and chronic (n = 40) schistosomiasis. Fifteen individuals at the acute phase were also evaluated 6 months after clinical diagnosis. Predominance of low-avidity IgG, IgG1, IgG2, IgG3 and IgA characterized the acute phase. IgG4 was detected in only 2 individuals with acute disease (5.6%). Levels of anti-SEA IgM were similar between the study groups. IgG1 avidity showed the strongest association with the chronological evolution of the infection, presenting 100% of low avidity during the acute infection and reaching 100% of high avidity 6 months after. It is suggested that distinct anti-Schistosoma egg antigens subclass profile and antibody avidity characterize the clinical phases of S. mansoni infection. In particular, determination of anti-SEA IgG1 offers a new tool for the laboratory analysis of the disease.
AuthorsL de G Viana, A Rabello, N Katz
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene (Trans R Soc Trop Med Hyg) 2001 Sep-Oct Vol. 95 Issue 5 Pg. 550-6 ISSN: 0035-9203 [Print] England
PMID11706672 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Helminth
  • Immunoglobulin G
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Animals
  • Antibodies, Helminth (immunology)
  • Antibody Affinity (immunology)
  • Child
  • Child, Preschool
  • Chronic Disease
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immunoglobulin G (immunology)
  • Infant
  • Middle Aged
  • Schistosoma mansoni (immunology)
  • Schistosomiasis mansoni (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: